Search results
Results From The WOW.Com Content Network
Jared Golden, D-Maine, posted on X, "At a time when we should be lowering prescription drug costs, this order by President Trump closes the door to $2 generics and cuts the ACA enrollment window ...
Denouncing the $557 billion industry as “horrible middlemen,” responsible for—and “rich as hell” from— America’s incomparably high prescription drug prices, Trump vowed to get rid of ...
The median price increase of the drugs being hiked Jan. 1 is 4.5%, which is in line with the median for all price increases last year. Drugmakers to raise US prices on over 250 medicines starting ...
We're going to get drug costs down at levels that nobody has ever seen before," Trump said. Shares of CVS fell 5.35% to $46.73, Cigna slipped 2.6% to $274.63, while UnitedHealth was down 3.54% at ...
Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a mixed bag. But headwinds, like tariffs and drug pricing, are clearly ...
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.
Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis.
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest prescription drugs once president-elect Donald Trump is back in office ...